Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 15/20 | 0.39 |
| ▸ | JAK2 | O60674 | 4/20 | 0.38 |
| ▸ | JAK1 | P23458 | 4/20 | 0.38 |
| ▸ | JAK3 | P52333 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19657299 | 0.81 | SYK (0.43) | CREBBPSYKJAK2JAK1JAK3 | |
| SCHEMBL19657744 | 0.78 | CREBBP (0.37) | CREBBPSYKJAK2JAK1JAK3 | |
| SCHEMBL21024071 | 0.76 | CREBBP (0.38) | CREBBPSYK | |
| SCHEMBL22822417 | 0.76 | SYK (0.49) | SYKJAK2JAK1JAK3 | |
| SCHEMBL29984777 | 0.74 | SYK (0.36) | CREBBPSYKJAK2JAK1JAK3 | |
| SCHEMBL9898861 | 0.74 | SYK (0.36) | CREBBPSYKJAK2JAK1JAK3 | |
| SCHEMBL12398487 | 0.72 | — | — | |
| SCHEMBL21024078 | 0.72 | SYK (0.40) | CREBBPSYKJAK2JAK1JAK3 | |
| SCHEMBL12398389 | 0.72 | — | — | |
| SCHEMBL21024114 | 0.71 | CREBBP (0.42) | CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168070-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200399244-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-12-24 | — | — | US | disclosed |
| US-10696655-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190152949-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399244-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC3 | CREBBP 7/4885SYK 1249/4885JAK2 130/4885 |
| US-20190152949-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC11 | CREBBP 6/4885SYK 1173/4885JAK2 117/4885 |
| US-11168070-B2 | Therapeutic compounds and uses thereof | EP300, HDAC1, HDAC11 | CREBBP 6/4885SYK 1173/4885JAK2 117/4885 |
| US-10696655-B2 | Therapeutic compounds and uses thereof | EP300, HDAC1, HDAC11 | CREBBP 6/4885SYK 1173/4885JAK2 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.